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Abstract
Background: PARP inhibitors have shown promising clinical results in cancer patients carrying BRCA1/2 mutations.
Their clinical efficacy could logically be influenced by PARP1 protein levels in patient tumors.
Methods: We screened three cohorts of patients with ovarian cancer, totaling 313 samples, and evaluated PARP1
protein expression by immunohistochemistry with further validation by western blotting.
Results: We observed that up to 60 % of tumors showed little PARP1 protein expression. In serous ovarian tumors,
comparing intratumoral PARP1 expression between chemo-naïve and post-chemotherapy patients revealed a decrease
in intratumoral PARP1 following chemotherapy in all three cohorts (immunohistochemistry: p < 0.001, n = 239; western
blot: p = 0.012, n = 74). The findings were further confirmed in a selection of matched samples from the same patients
before and after chemotherapy.
Conclusion: Our data suggest that patients should be screened for PARP1 expression prior to therapy with PARP
inhibitors. Further, the observed reduction of intratumoral PARP1 post-chemotherapy suggests that treating
chemo-naïve patients with PARP inhibitors prior to the administration of chemotherapy, or concurrently, might
increase the responsiveness to PARP1 inhibition. Thus, a change in the timing of PARP inhibitor administration may be
warranted for future clinical trials.
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Background
Unlike breast cancer, the overall survival of patients with
ovarian cancer has shown only slight improvement over
the past 30 years [1], with high-grade serous cancers
(HGSC) of the ovary being the most deadly gynecologic
cancer. While many patients with HGSC respond to
first-line chemotherapy, recurrence and drug resistance
occur in the vast majority of cases [2]. Identification of
key biomarkers or predictors for response to one or a
combination of specific antitumor drugs seems essential.
Over the past 5 years, clinical trials using various PARP in-
hibitors on patients with BRCA1/2 mutations [3, 4] have
shown promising results [5]. Inherent defects in the
homologous recombination DNA repair pathway in
BRCA-deficient tumors coupled with the inhibition of
PARP1 lead to a synthetic lethality culminating in
cancer cell death [6]. It is estimated that almost half
of patients with HGSC bear defects in homologous
recombination [7], spurring the onset of clinical trials
to test PARP inhibitors in this population.
The reported response rate for BRCA-deficient HGSC
in the ovary treated with PARP inhibitors ranges between
25 and 53 % [5, 8–12]. In these published studies, enrolled
patients had received several cycles of adjuvant chemo-
therapy prior to PARP inhibitors.
In this study, we evaluated the effect of chemotherapy
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Neo-adjuvant chemotherapy consisted of three to four
combined courses of a platinum-based agent (carboplatin)
and paclitaxel given prior to surgery. Changes to this
protocol were made depending on the patient's condi-
tion, response, compliance, and side effects. The pa-
tients were considered responsive to this regimen if
recurrence occurred more than 6 months after the last
chemotherapy treatment.
Training cohort: immunohistochemistry (IHC) analysis
Tumor samples were obtained from 69 patients who had
undergone surgery and chemotherapy in the Division of
Gynecologic Oncology of McGill University’s Jewish
General Hospital from 2006 to 2014 (Table 1). Diagnosis
was based on final pathology, determined by an inde-
pendent gynecologic pathologist. The tumors were
staged according to the International Federation of
Gynecology and Obstetrics (FIGO) stage and histologi-
cally classified and graded according to the World
Health Organization grade. Tissue selection criteria for
this study were based on chemotherapy-naïve and
chemotherapy-treated patients.
Validation cohort 1: Tissue microarray (TMA)
Tumor samples were obtained from 170 patients who had
undergone surgery for ovarian cancer at the Department of
Gynecologic Oncology Centre Hospitalier de l’Université
de Montréal (Table 2). An independent pathologist
reviewed tumor histopathology, grade, and chemother-
apy status of each patient. Tissue selection criteria for
this study were based on chemotherapy-naïve and
chemotherapy-treated patients. Samples were collected
between 1993 and 2014.
Validation cohort 2: western blot analysis
Tissue samples were included from 74 patients (mean
age 60.7, range 24–87) with ovarian cancer who had
undergone surgery and chemotherapy in the Jewish
General Hospital from 2004 to 2013 (Table 3). The pa-
tient’s course of treatment was determined by a team of
gynecologic oncologists in accordance with the National
Comprehensive Cancer Network guidelines.
Ethical approval
The research complied with all requirements of the
Helsinki Declaration. Tissue samples were taken from the




Age (years), mean (range) 61.9 (36–86)
Histology Serous 69 (100)




Grade 1 2 (3)
2 3 (4)
3 57 (83)
Chemotherapy Neo-adjuvant 35 (51)
Adjuvant 32 (46)
Surgery Not robotic 32 (46)
Robotic 35 (51)
Residual disease 4 (6)
Response Responsive 41 (59)
Resistant 19 (28)
Recurrence Number 41 (59)
Mean time (range) 17.9 months (3–84)
Deceased Number 21 (30.4)
Mean time (range) 27.9 months(10–72)
Follow-up Mean time (range) 36.6 months (7–111)
Table 2 Validation cohort 1: clinical characteristics of patients
for tissue microarray experiment
Patients Number (%)
Number 170
Age (years), mean (range) 52 (39–93)
Histology Serous 150 (88.2)
Non serous 20 (11.8)




Grade 1 6 (3.5)
2 22 (12.9)
3 136 (80)
Chemotherapy Neo-adjuvant 85 (50)
Adjuvant 85 (50)
Residual disease ≤1 cm 87 (51.2)
≥1 cm 57 (33.5)
Not determined 26 (15.3)
Response Responsive 123 (72.3)
Resistant 47 (27.7)
Recurrence Number 128 (75.3)
Mean time (range) 20 months (2–76)
Deceased Number 105 (61.8)
Mean time (range) 47 months (2–156)
Follow up Mean time (range) 43 months (2–73)
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gynecologic oncology tumor bank and approved by the
Jewish General Hospital (protocol#14-025). Ethic approval
was obtained from the Jewish General Hospital Research
Ethics Committee (protocol#03-041). All patients partici-
pating in this study gave informed written consent.
PARP1 antibody validation
PARP1 antibody (Clone B-10, sc74470, Santa Cruz
Biotechnology, Inc. Dallas, TX, USA) specificity was vali-
dated for both western blot and IHC (Additional file 1:
Figure S1). Epithelial ovarian cancer cells OVCAR8 were
infected using shctl or shPARP1. After 5 days, cells were
collected and either fixed in formalin for IHC analysis or
proteins were extracted for western blot analysis.
Immunohistochemistry
Biopsies and surgical specimens were formalin-fixed at
the Pathology Facility (Jewish General Hospital) for 12 h
at room temperature, processed, and paraffin-embedded.
IHC staining was performed at the Segal Cancer Center
Research Pathology Facility as previously described [13].
Briefly, tissue samples were cut at 4 μm, placed on
SuperFrost/Plus slides (Fisher Scientific, Pittsburgh, PA,
USA), and dried overnight at 37 °C. The slides were then
loaded onto the Discovery XT Autostainer (Ventana
Medical Systems, Inc. Tucson, AZ, USA). All solutions
used for automated IHC were from Ventana Medical
Systems unless otherwise specified. Slides underwent de-
paraffinization with the EZ PREP solution (Ref# 950–100),
followed by heat-induced epitope retrieval with Cell Con-
ditioning Solution 1, pH 8.0 (Ref# 950–224), in standard
conditions (60 min at 95 °C). Immunostaining for PARP1
was performed online using a heat protocol. Briefly,
mouse monoclonal anti-PARP1 (B-10, sc74470, Santa
Cruz Biotechnology, Inc.) diluted at 1:100 in antibody di-
luent (Ref# 251–018) was manually applied for 32 min at
37 °C, then PARP1 protein was detected using Omnimap
anti-Mouse HRP Kit (Ref# 760–4310) and ChromoMap-
DAB (Ref# 760–159). Slides were counterstained with
hematoxylin for 4 min; blued with Bluing Reagent for
4 min; removed from the autostainer; washed in warm
soapy water (Dawn) dehydrated through graded alcohols;
cleared in xylene; and mounted with Permount. The per-
centage of tumor cells stained was assessed by an experi-
enced pathologist (MP, assisted by MM, M-CB and IL)
and ranked as follow: 0 = no staining, 1 = <25 % staining,
2 = 25–50 %, 3 = >75 %. The intensity of the staining was
ranked as follow: 0 = no staining, 1 = mild staining, 2 =
moderate staining, 3 = strong staining. Scores for percent-
age of distribution and intensity were multiplied by each
other to reach a final score ranging between 0 and 9 (in-
tensity × distribution) for comparison analysis. For TMA
analysis, the intensity of staining was evaluated by two
people blinded to the identification of the cores. More
than 80 % of similarity was observed between the two in-
dependent scores. Only tumor tissue was taken into
account for the score calculation.
Pre-post chemotherapy epithelial ovarian tumor
tissue microarray
A gynecologic pathologist reviewed all samples pre-
chemotherapy and post-chemotherapy to identify the
grade and type of ovarian carcinoma. Areas of interest
were marked on slides. Two cores of 0.6 mm for each
tissue sample were arrayed onto one recipient paraffin
block. This tissue array was composed of cores from 170
epithelial ovarian tumors (two cores per patient sample)
and was built on two recipient blocks.
Protein extraction and western blot analysis
In total, 100 unselected tumor samples from 74 patients
(cohort 3) were analyzed, comprising 21 ascites cells pel-
let, 57 primary tumors, 18 omental tumors, and 4 other
tumor tissues. Similar levels of PARP1 protein were ob-
served between the tumor and the omentum isolated
from the same patient at the time of surgery (data not
Table 3 Validation cohort 2: clinical characteristics of patients
for western blot experiment
Patients Number (%)
Number 74
Age(y), mean(range) 60.7 (24–87)
Histology Serous 48 (64.9)
Non Serous 26 (35.1)




Grade 1 9 (16.9)
2 5 (9.4)
3 39 (73.6)
Chemotherapy Neo-adjuvant 34 (46)
Adjuvant 25 (34)
Surgery Laparotomy 30 (46)
Laparoscopy 2 (3)
Robotic 33 (51)
Residual disease 8 (10.8)
Response Responsive 33 (75)
Resistant 11 (25)
Recurrence Number 27 (36.5)
Mean time (range) 9.6 months (3–29)
Deceased Number 21 (31.3)
Mean time (range) 26.5 months (4–88)
Follow-up Mean time (range) 31.4 months (7–107)
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shown). Snap-frozen tumor tissues were minced and
lysed in lysis buffer (25 mM Tris∙HCl pH 7.6, 10 % gly-
cerol, 420 mM NaCl, 2 mM MgCl2, 0.5 % NP-40, 0.5 %
Triton X-100, 1 mM EDTA, protease inhibitor) on ice.
Briefly, clarified protein lysates (50 μg) were resolved on
6 % and 10 % denaturing SDS-polyacrylamide gels, and
transferred to nitrocellulose membranes, similar to as
previously described [14]. After blocking in 5 % milk,
membranes were probed with primary antibodies spe-
cific for BRCA1 (cat#OP92, Calbiochem, Gibbstown, NJ,
USA), PARP1 (sc74470), and β-actin (Cell Signaling
Technology, Whitby, Ontario, Canada). Immunoblotted
proteins were visualized using horseradish peroxidase-
conjugated secondary antibodies and antigen-antibody
complexes were detected using the ECL system (Bio-Rad
Laboratories, Inc. Hercules, CA, USA).
Statistical analysis
Statistical analysis was performed using SPSS (version
22) and R (version 3.1.0). The data were assessed as
nonparametric data. A χ2 test was used to analyze the ef-
fect of chemotherapy on PARP1 and BRCA1 protein
level [15]. We used a two-tailed Mann–Whitney U test
to analyze dependency between treatment and PARP1
protein quantity [16]. A two-tailed Wilcoxon signed
ranks test was used to evaluate this phenomenon in the
same patient before and after chemotherapeutic treat-
ment [15]. Differences with a p-value < 0.05 were con-
sidered statistically significant.
Results and discussion
We first analyzed gene expression (n = 570) and reverse-
phase protein analysis (n = 412) data made publically
available from The Cancer Genome Atlas (TCGA) web-
site for HGSC and found low PARP1 protein levels in a
majority of the tumors (Fig. 1), consistent with previous
findings in breast tumors [17]. These data prompted us
to evaluate PARP1 protein levels in a set of 69 HGSC by
IHC (training cohort). Of these, 71 % were characterized
as having low PARP1 expression (Fig. 1b,c). This data was
Fig. 1 Low PARP1 protein expression in ovarian tumors. a Analysis of The Cancer Genome Atlas (TCGA) ovarian cystadenocarcinoma database for
PARP1 mRNA (n = 570) and protein (n = 412) expression levels. Data were used to generate a heat map with red representing high expression
level and green low expression level. b Pie chart representing PARP1 protein level as determined by immunohistochemistry (IHC) in 69 HGSC
samples (training cohort). c PARP1 representative IHC for each expression category (low and high). d Pie chart distribution of PARP1 in 100
unselected ovarian tumors from 74 patients (validation cohort 2, several patients had multiple tumors examined) evaluated by western blotting.
e PARP1 representative western blot for each expression category (low, high, and negative); OVCAR4 protein extract was used as positive control.
f Pie chart representing BRCA1 protein level distribution from 74 patients (100 tumors, validation cohort 2) evaluated by western blotting
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further validated using western blotting of tumors from 74
unselected patients with ovarian cancer (validation cohort
2). PARP1 protein expression was undetectable in 60 % of
the tumors analyzed (Fig. 1d,e), similar to our IHC data
and previously published studies [18, 19]. Of the 100 tu-
mors we analyzed from the 74-patient cohort by west-
ern blotting, we further observed 77 % of them had
undetectable BRCA1 protein levels (Fig. 1f ), and found
Fig. 2 Chemo-treated tumors have lower levels of PARP1 protein than chemo-naïve tumors. a We used 69 HGSC tumors for immunohistochemistry
(IHC) staining of PARP1 (training cohort). Each slide score is the product of the percentage of stained tumors cells and the intensity of the staining as
described in the “Methods” section. The bar graph represents the percentage of slides with scores in the upper tertile from chemo-naïve and
chemo-treated samples. Chi-square test p < 0.001. b Representative photos of PARP1 IHC from two chemo-naïve tumors and two chemo-treated
tumors (20×). c Boxplot showing compilation of PARP1 intensity of staining score for the tissue microarray (TMA). The p-value tested whether there
was a significant difference in PARP1 staining intensity between the chemo-naïve and chemo-treated tumors and was calculated using a two-tailed
Mann–Whitney test. d Representative TMA cores stain with PARP1 antibody. e PARP1 protein levels in 62 serous ovarian cancer (SOC) tumors
(30 chemo-naïve and 32 chemo-treated) were quantified with ImageJ and the density signals obtained were used to generate a boxplot. Wilcox
Mann–Whitney test gave p = 0.01246. f Representative western blots of PARP1 in three chemo-naïve tumors and three chemo-treated tumors from
cohort shown in e
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the same ratio of PARP1-expressing and BRCA1-
expressing tumors as seen in previous studies [18, 19].
This suggests that samples within this cohort are highly
representative of HGSC cohorts examined by other groups.
Because of the increasing use of neo-adjuvant therapy, we
had the opportunity to evaluate PARP1 expression in can-
cers before and after chemotherapy and evaluate whether
exposure to chemotherapy might play a role in the levels
of PARP1 in ovarian tumor. We selected tumor samples
from patients with HGSC and compared PARP1 protein
levels between chemo-naïve and chemo-treated tumors
with standard chemotherapy (carboplatin + taxol) in three
patient cohorts: a training cohort (IHC, 69 HGSC samples),
validation cohort 1 (IHC, 170 HGSC samples), and valid-
ation cohort 2 (western blotting, 74 patients, 62 HGSC
samples). We found a significant reduction of PARP1 pro-
tein by IHC on the training cohort of 31 chemo-naïve and
38 chemo-treated HGSC (Fig. 2a and Table 1). The propor-
tion of tumors with high PARP1 expression was halved in
chemo-treated samples compared to the chemo-naïve tu-
mors (Fig. 2a,b). We next validated these results using val-
idation cohort 1 for a TMA (Fig. 2c,d and Table 2) and
validation cohort 2 for western blotting (Fig. 2e,f and
Table 3). In both groups, we found a significant reduction
of PARP1 expression in the chemo-exposed tumors.
Amongst our samples, we identified 15 matched sam-
ples isolated from individual patients from whom a tumor
sample was available before and after chemotherapy. Of
the patients tested, six showed no PARP1 protein expres-
sion. Of the remaining nine, eight had reduced PARP1
protein levels post-chemotherapy (Fig. 3a–c). We further
confirmed these results by IHC (Fig. 3d). Although sur-
prising, our results might explain the low, or absent,
PARP1 protein seen in a large proportion of the ovarian
tumors tested in previous studies [18, 19]. Altogether,
these data strongly suggest a suppressive effect of chemo-
therapy on PARP1 protein expression in solid tumors.
Next, we documented the time between the last
chemotherapy treatment and the time at which the bi-
opsy was taken in PARP1-positive and PARP1-negative
tumors and found no difference (16.5 days versus
17.0 days). This suggests that the reduction of PARP1 in
the tumors was stable and represents a switch in the
molecular pathways of the remaining tumor cells post-
Fig. 3 Chemotherapy decreases PARP1 protein levels in matched patient samples. a PARP1 protein levels in tumor samples from the same 15 patients
before and after chemotherapy were quantified with ImageJ and the density signals obtained were used to generate a boxplot. Paired Mann–Whitney
test p = 0.03734. b PARP1 density signals from nine patients with the presence of PARP1 in the tumors before receiving chemotherapy. c Representative
PARP1 and actin western blot of three matched tumor samples before (CN) and after (CT) receiving chemotherapy treatment. d PARP1
immunohistochemistry (IHC) staining in tumor before and after chemotherapy treatment in the same patients (20×)
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chemotherapy or the selection of residual cells that have
low PARP1 expression.
In addition, we evaluated whether the expression of
PARP1 contributes to platinum sensitivity (defined as no
tumor recurrence for greater than 6 months as per
“Methods”). These data were available for the 69 tumors
within our training cohort. Notably, we found that tu-
mors with high PARP1 expression were significantly
more platinum sensitive than low PARP1 expression tu-
mors, independent of previous chemotherapy exposure
in the training cohort (χ2 test, p < 0.001). This may be
associated with the fact that PARP1 is an important me-
diator of cell death in response to stress [20].
We also confirmed using the training cohort that
BRCA1-deficient tumors were associated with platinum
sensitivity (χ2 test, p < 0.001). Taken together, these find-
ings reinforce the idea that platinum-sensitive BRCA1-
deficient tumors might respond better to PARP inhibi-
tors when intratumoral PARP1 levels are high.
It is expected that PARP1 expression and a loss of
functional BRCA1 are required for sensitivity to PARP
inhibitors. In validation cohort 2, the BRCA1-negative,
PARP1-positive subset of tumors represented 32.7 % of
serous ovarian cancer patients in this study. Strikingly,
this number is similar to the proportion of reported
positive objective response rate in clinical trials with
Olaparib (41 % [10], 33 % [8], and 25–31 % [11]). More-
over, no impact of chemotherapy on BRCA1 protein sta-
tus could be discerned, emphasizing the specificity of
the findings. The results suggest that patients receiving
PARP inhibitors could be selected not only based on
their BRCA1 status, but also for PARP1 protein expres-
sion. Such screening is commonplace for other targeted
therapies, such as aromatase inhibitors or vemurafenib
[21, 22], and could be integrated into standard operating
procedures for pathologists and oncologists. This con-
cept will be explored in the future within our depart-
ment. Based on our data, we predict this screening
approach would substantially expand the positive object-
ive response rates.
Conclusion
To our knowledge, this study is the first to probe the
effect of chemotherapy treatment on PARP1 protein
expression in HGSC. Considering that all patients en-
rolled in previous clinical trials received several cycles
of chemotherapy prior to receiving PARP inhibitor
treatment [5, 8–12], these data are likely relevant for
guiding future administration of PARP inhibitor ther-
apy. Further studies with independent cohorts are thus
warranted to evaluate the effect of PARP1 protein ex-
pression on the efficacy of PARP inhibitors. These
observations suggest that co-application of PARP
inhibitors and chemotherapy as frontline therapy might
yield significantly better outcome in HGSC, and could
also be explored in other patients with homologous
recombination-deficient cancers.
Additional file
Additional file 1: Figure S1. PARP1 antibody validation. (A) Western
blot of PARP1 and actin were performed on OVCAR8 cells infected with
shRNA control or directed against PARP1. (B) The same cells used in (A)
were paraffin-embedded and IHC staining against PARP1 was performed
using the same antibody as in (A). The antibody shows high specificity
and sensitivity for PARP1 protein in both techniques. (TIFF 1130 kb)
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